BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31436242)

  • 21. Analysis of the causes of failure after radical surgery in patients with
    Shen WB; Gao HM; Zhu SC; Li YM; Li SG; Xu JR
    World J Surg Oncol; 2017 Oct; 15(1):192. PubMed ID: 29070049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Factors affecting on long-time survival in patients with stage Ⅲ thoracic esophageal carcinoma after esophagectomy].
    Yang Q; Wang YX; He M; Li J; Qi Z; Zhu SC; Qiao XY
    Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):530-7. PubMed ID: 27531268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.
    Deng W; Zhang W; Yang J; Ni W; Yu S; Li C; Chang X; Zhou Z; Chen D; Feng Q; Chen X; Lin Y; Zhu K; Zheng X; He J; Gao S; Xue Q; Mao Y; Cheng G; Sun K; Liu X; Fang D; Chen J; Xiao Z
    Ann Surg Oncol; 2019 Sep; 26(9):2890-2898. PubMed ID: 31183641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis.
    Li CC; Chen CY; Chien CR
    Medicine (Baltimore); 2018 Jun; 97(22):e10928. PubMed ID: 29851829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
    Wu X; Hu X; Chen J; He L
    Radiat Oncol; 2021 Jun; 16(1):100. PubMed ID: 34103059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
    Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
    [No Abstract]   [Full Text] [Related]  

  • 28. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial.
    Li B; Hu H; Zhang Y; Zhang J; Miao L; Ma L; Luo X; Zhang Y; Ye T; Li H; Zhou J; Li Y; Shen L; Zhao K; Fan M; Zhu Z; Wang J; Xu J; Deng Y; Lu Q; Jia H; Cheng X; Li H; Zhang Y; Li C; Pan Y; Liu S; Hu H; Shao L; Sun Y; Xiang J; Chen H
    Ann Surg; 2018 May; 267(5):826-832. PubMed ID: 28448385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between Esophagectomy and Definitive Chemoradiotherapy in Patients With Esophageal Cancer.
    Wang BY; Hung WH; Wu SC; Chen HC; Huang CL; Lin CH; Chen HS
    Ann Thorac Surg; 2019 Apr; 107(4):1060-1067. PubMed ID: 30571951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping patterns of metastatic lymph nodes for postoperative radiotherapy in thoracic esophageal squamous cell carcinoma: a recommendation for clinical target volume definition.
    Yu J; Ouyang W; Li C; Shen J; Xu Y; Zhang J; Xie C
    BMC Cancer; 2019 Sep; 19(1):927. PubMed ID: 31533656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of image-guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy.
    Kuo YH; Fang HY; Lin YS; Lein MY; Yang CY; Ho SC; Li CC; Chien CR
    Thorac Cancer; 2020 Jan; 11(1):113-119. PubMed ID: 31742897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
    Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
    Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma: a multicenter retrospective study.
    Nakajo K; Abe S; Oda I; Ishihara R; Tanaka M; Yoshio T; Katada C; Yano T
    J Gastroenterol; 2019 Oct; 54(10):871-880. PubMed ID: 31055660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.